SynthesisBMC psychology2026
The impact of schema therapy and its basic and mode treatment models for depressive disorders: a systematic review.
Synthesis in BMC psychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh depression rates persist despite the availability of gold-standard psychological treatments. There is growing research evidence for schema therapy's effectiveness for depression. However, the adoption of schema therapy in clinical practice has outstripped the pace of research. The most recent model of schema therapy (the mode model) is increasingly being used over the basic model because of its experiential techniques and expansion beyond early maladaptive schemas. This systematic review aimed to explore the impact of schema therapy and its treatment models (basic and mode) on symptom reduction in depressive disorders.
methodA systematic literature search was conducted in PsycINFO, MEDLINE, Embase, Scopus, and the Cochrane Library on 23 November 2023 and updated on 1 June 2024. Studies were excluded if they used combined therapies, child samples, or lacked a formal depression diagnosis, depressive outcome data, or an English translation. The review was conducted following PRISMA guidelines and study quality was evaluated using the Joanna Briggs Institute Critical Appraisal Checklists.
resultsSeven studies (N = 580) with a range of methodological designs, outcomes measures, and diagnoses were identified. All studies found that schema therapy had a significantly positive impact on depressive outcomes and large effect sizes pre-post treatment were observed. The studies suggest that schema therapy was non-inferior to established treatments such as CBT and had similar efficacy to short-term psychoanalytic supportive psychotherapy and individual supportive therapy. Included studies also indicated that the dosage of sessions may be important in ensuring significantly large treatment effects.
conclusionsThe literature indicates that schema therapy is effective for reducing depressive symptoms in depressive disorders. The strength of the findings are limited by the modest number of studies and sample sizes therein. However, current evidence lends more support to the mode model's effectiveness in depressive symptom reduction. Higher schema therapy dosage may elicit pronounced treatment benefits for depressive disorders, even with chronic and comorbid psychopathologies. Comparative RCTs of the different schema therapy models and between schema therapy and CBT are required to advance the evidence base. SYSTEMATIC REVIEW REGISTRATION: PROSPERO (CRD42023480067).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.